Document Detail


New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.
MedLine Citation:
PMID:  22205621     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.
Authors:
Jing Tong; You-wei Wang; Yuan-an Lu
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of Zhejiang University. Science. B     Volume:  13     ISSN:  1862-1783     ISO Abbreviation:  J Zhejiang Univ Sci B     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-29     Completed Date:  2012-04-26     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101236535     Medline TA:  J Zhejiang Univ Sci B     Country:  China    
Other Details:
Languages:  eng     Pagination:  56-82     Citation Subset:  IM    
Affiliation:
Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii 96822, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / pharmacology*,  therapeutic use
Clinical Trials as Topic
Enzyme Inhibitors / pharmacology*,  therapeutic use
Hepacivirus*
Hepatitis C, Chronic / drug therapy*
Humans
Grant Support
ID/Acronym/Agency:
P50ES012740/ES/NIEHS NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Enzyme Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical characteristics of critical patients with pandemic influenza A (H1N1) virus infection in Ch...
Next Document:  Delayed matching to sample: reinforcement has opposite effects on resistance to change in two relate...